Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Vaccines

Free Subscription Articles published in PLoS Med Retrieve available abstracts of 21 articles: HTML format

Single Articles

November 2025
1. JIAO B, Sato R, Mak J, Patenaude B, et al
   Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling study.
   PLoS Med. 2025;22:e1004764.
   PubMed     Abstract available
   
   
   October 2025
2. KAWAMOTO A, Hashida M, Ishida K, Furihata K, et al
   Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.
   PLoS Med. 2025;22:e1004499.
   PubMed     Abstract available
   
   
   
3. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
   Correction: Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
   PLoS Med. 2025;22:e1004789.
   PubMed     Abstract available
   
   
   September 2025
4. MANDOLO J, Mulira L, Moyo M, Mvula M, et al
   Maternal-infant rotavirus-specific antibody kinetics to inform timing of vaccine boosting in Malawi: An observational study.
   PLoS Med. 2025;22:e1004734.
   PubMed     Abstract available
   
   
   
5. JIN S, Asakura TR, Murayama H, Niyukuri D, et al
   Vaccination strategies to achieve outbreak control for MPXV Clade I with a one-time mass campaign in sub-Saharan Africa: A scenario-based modelling study.
   PLoS Med. 2025;22:e1004726.
   PubMed     Abstract available
   
   
   July 2025
6. LI J, Li Y, Qin C, He Y, et al
   Effect of a pay-it-forward strategy on reducing HPV vaccine delay and increasing uptake among 15- to 18-year-old girls in China: A randomized controlled trial.
   PLoS Med. 2025;22:e1004535.
   PubMed     Abstract available
   
   
   June 2025
7. GOODFELLOW L, Procter SR, Koltai M, Waterlow NR, et al
   The potential global health impact and cost-effectiveness of next-generation influenza vaccines: A modelling analysis.
   PLoS Med. 2025;22:e1004655.
   PubMed     Abstract available
   
   
   
8. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
   Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
   PLoS Med. 2025;22:e1004631.
   PubMed     Abstract available
   
   
   April 2025
9. 
   Correction: Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
   PLoS Med. 2025;22:e1004605.
   PubMed     Abstract available
   
   
   February 2025
10. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004521.
    PubMed     Abstract available
    
    
    
11. INGABIRE R, Nyombayire J, Mazzei A, Mazarati JB, et al
    Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
    PLoS Med. 2025;22:e1004508.
    PubMed     Abstract available
    
    
    
12. GRAIS RF, Neuzil KM, Rees H, Toscano CM, et al
    Protecting mother and baby: Learnings from an Ebola vaccination campaign on the evolving landscape of vaccines and pregnancy.
    PLoS Med. 2025;22:e1004530.
    PubMed     Abstract available
    
    
    
13. GUTTIERES D, Diepvens C, Grais RF, Kiarie J, et al
    Charting a novel path towards Ebola virus disease preparedness: Considerations for preventive vaccination.
    PLoS Med. 2025;22:e1004543.
    PubMed     Abstract available
    
    
    January 2025
14. SEIDLEIN LV
    Roll out and prospects of the malaria vaccine R21/Matrix-M.
    PLoS Med. 2025;22:e1004515.
    PubMed     Abstract available
    
    
    
15. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Correction: Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004573.
    PubMed     Abstract available
    
    
    October 2024
16. MUNDAY JD, Atkins KE, Klinkenberg D, Meurs M, et al
    Estimating the risk and spatial spread of measles in populations with high MMR uptake: Using school-household networks to understand the 2013 to 2014 outbreak in the Netherlands.
    PLoS Med. 2024;21:e1004466.
    PubMed     Abstract available
    
    
    September 2024
17. INIZAN C, Courtot A, Sturmach C, Griffon AF, et al
    Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.
    PLoS Med. 2024;21:e1004397.
    PubMed     Abstract available
    
    
    June 2024
18. PEREZ CHACON G, Estcourt MJ, Totterdell J, Marsh JA, et al
    Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
    PLoS Med. 2024;21:e1004414.
    PubMed     Abstract available
    
    
    
19. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
    Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
    PLoS Med. 2024;21:e1004375.
    PubMed     Abstract available
    
    
    April 2024
20. JUNG SM, Loo SL, Howerton E, Contamin L, et al
    Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
    PLoS Med. 2024;21:e1004387.
    PubMed     Abstract available
    
    
    March 2024
21. MOODIE Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, et al
    Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    PLoS Med. 2024;21:e1004360.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.